Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial

Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice

(2015) Z. Lin et al.   CIRCULATION

The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy

(2015) Jia Liu et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Effect of dietary lipids on circulating adiponectin: a systematic review with meta-analysis of randomised controlled trials

(2014) Anize D. von Frankenberg et al.   BRITISH JOURNAL OF NUTRITION

Fibroblast Growth Factor-21 and the Beneficial Effects of Long-Chain n-3 Polyunsaturated Fatty Acids

(2014) Joan Villarroya et al.   LIPIDS

Fish or n3-PUFA intake and body composition: a systematic review and meta-analysis

(2014) N. Bender et al.   Obesity Reviews

Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice

(2013) Zhuofeng Lin et al.   Cell Metabolism

An FGF21-Adiponectin-Ceramide Axis Controls Energy Expenditure and Insulin Action in Mice

(2013) William L. Holland et al.   Cell Metabolism

Omega-3 fatty acids: a review of the effects on adiponectin and leptin and potential implications for obesity management

(2013) B Gray et al.   EUROPEAN JOURNAL OF CLINICAL NUTRITION

Adiponectin oligomers as potential indicators of adipose tissue improvement in obese subjects

(2013) Anna De Rosa et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Circulating Levels of FGF-21 in Obese Youth: Associations With Liver Fat Content and Markers of Liver Damage

(2013) Cosimo Giannini et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Daidzein Supplementation Decreases Serum Triglyceride and Uric Acid Concentrations in Hypercholesterolemic Adults with the Effect on Triglycerides Being Greater in Those with the GA Compared with the GG Genotype of ESR-β RsaI

(2013) Yu Qin et al.   JOURNAL OF NUTRITION

Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients

(2013) Fitsum Guebre-Egziabher et al.   NUTRITION

Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids

(2013) Dimitrios G Bouzianas et al.   NUTRITION REVIEWS

High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: A 3-year prospective study in China

(2012) Huating Li et al.   JOURNAL OF HEPATOLOGY

Docosahexaenoic acid for the treatment of fatty liver: Randomised controlled trial in children

(2012) V. Nobili et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Low-dose fish oil supplementation increases serum adiponectin without affecting inflammatory markers in overweight subjects

(2012) Anders Gammelmark et al.   NUTRITION RESEARCH

Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial

(2011) V. Nobili et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

(2011) S. L. Samson et al.   DIABETOLOGIA

Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis

(2011) Helen M. Parker et al.   JOURNAL OF HEPATOLOGY

Effects of Short-Term Continuous Subcutaneous Insulin Infusion on Fasting Plasma Fibroblast Growth Factor-21 Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

(2011) Mengliu Yang et al.   PLoS One

Fish Oil for the Treatment of Cardiovascular Disease

(2010) Daniel Weitz et al.   Cardiology in Review

The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease

(2010) Haim Shapiro et al.   CLINICAL NUTRITION

Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State

(2010) f. M. Fisher et al.   DIABETES

Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes

(2010) Kazuhiro Eto et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease

(2010) Yusuf Yilmaz et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease

(2010) Jody Dushay et al.   GASTROENTEROLOGY

Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride

(2010) Huating Li et al.   JOURNAL OF HEPATOLOGY

Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance

(2009) A. O. Chavez et al.   DIABETES CARE

Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus

(2009) C.-Y. Wong et al.   DIABETIC MEDICINE

Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus

(2009) Ke Li et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study

(2009) Ariel E. Feldstein et al.   HEPATOLOGY

Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity

(2008) M. Mraz et al.   CLINICAL ENDOCRINOLOGY

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

(2008) J. Xu et al.   DIABETES